Yoko Bean, MD
Urogynecology and Reconstructive Pelvic Surgery · Los Angeles, CANPI 1366822025
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,156 of the $8,813 with a category attached, or 81.2%. 16 manufacturers reported payments, led by Coloplast at 32.5% of the total. 2025 is the largest year on record at $2,139, 3.0 times the $708 reported in 2019.
Across 208 payments — averaging $42.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coloplast$3K
- Medtronic$2K
- Axonics, Inc.$1K
- Bluewind Medical$839
- Boston Scientific$606
- AbbVie$370
- plus $639 from 10 others
Across 1 payment — averaging $14,850 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$15K
What the payments were for
- Travel & lodging$1,10012%
- Food & beverage$7,15681%
- Education$5576%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coloplast | 35 | $2,865 |
| Medtronic(2 entities) | 80 | $2,015 |
| Axonics, Inc. | 33 | $1,478 |
| Bluewind Medical | 13 | $839 |
| Boston Scientific | 11 | $606 |
| AbbVie(2 entities) | 16 | $370 |
| Astellas Pharma US Inc | 7 | $284 |
| Sumitomo Pharma America, Inc. | 3 | $80 |
| 180 Medical, Inc. | 2 | $50 |
| Applied Medical Resources Corporation | 1 | $45 |
| Urovant Sciences Inc | 2 | $42 |
| Intuitive Surgical | 1 | $31 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $31 |
| Valencia Technologies Corporation | 1 | $29 |
| Pfizer | 1 | $24 |
| Bayer | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ALTIS$1,637
- Axonics$821
- INTERSTIM$684
- SUPRIS$342
- REVI$253
- RESTORELLE$200
- ALTAVIVA$156
- Saffron$118
- GENERAL FEMALE SUI$115
- SOLYX$111
- Axonics r-SNM System$108
How this compares
$8,813 in reported general payments places this provider in the 70th percentile of 130 urogynecology and reconstructive pelvic surgery providers in California.
See all urogynecology and reconstructive pelvic surgery providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 233 | $238,559 |
| MyrbetriqMirabegron | 125 | $113,870 |
| PremarinEstrogens, Conjugated | 97 | $41,504 |
| Trospium Chloride ErTrospium Chloride | 68 | $13,476 |
| EstringEstradiol | 22 | $11,097 |
| Estradiol | 172 | $10,337 |
| Methenamine Hippurate | 87 | $6,996 |
| Trospium Chloride | 50 | $3,398 |
| YuvafemEstradiol | 19 | $3,347 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 142 | $1,563 |
| NitrofurantoinNitrofurantoin Macrocrystal | 42 | $1,046 |
| Gabapentin | 23 | $225 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 73 | $218 |
| Ibuprofen | 41 | $213 |
| Cefdinir | 19 | $150 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $80 | $238,559233 claims |
| Astellas Pharma US IncMyrbetriq | $284 | $113,870125 claims |
| PfizerPremarin, Estring | $24 | $52,601119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 130 urogynecology and reconstructive pelvic surgery providers in California.
Other urogynecology and reconstructive pelvic surgery in Los Angeles
- Tanaz FerzandiLos Angeles$60K
- Christopher TarnayLos Angeles$41K
- Anne AckermanLos Angeles$32K
- Darlene MorrisseyLos Angeles$10K
- Victoria ScottLos Angeles$5K
- Thinh DuongLos Angeles$5K
- Victor VelascoLos Angeles$5K
- Andrey PetrikovetsLos Angeles$5K
- Atieh NovinLos Angeles$5K
- Michele TorosisLos Angeles$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.